A subgroup analysis by weight reduction iced the case for proportionate benefit of symptom relief and less inflammation (by biomarkers) as a function of weight loss These are striking results for people with HFpEf given the only other drugs that have thus far shown benefit are the sodium-glucose cotransporter 2 (SGLT2) inhibitors
Federal law allows states to exclude agents used for weight loss from their Medicaid formularies so covering GLP-1s for obesity is optional, not required
: Menopause journals.lww.com/menopausejourn I love seeing research in the menopausal/HRT field, but n=16 makes type 1 error highly likely, and I bet most people reading this headline will just take it for conclusions Join the conversation
doi: 10.1056/NEJMoa2108269 16 DaviesMJD'AlessioDAFradkinJKernanWNMathieuCMingroneGet al
Consistent protein intake, strength training, adequate sleep, and stress management amplify the medication's effect and help you break through plateaus without increasing injection volume
These mice had less pain, less broken-down cartilage and more cartilage growth, the team found